<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - MORPHINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>MORPHINE</h1>

        <p><a href="../drugClass/PHP34573.html">OPIOIDS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by rectum</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1&#8211;5 months</strong><br/>
                Initially 100&#8211;200 micrograms/kg every 6 hours, adjusted according to response.</li>
              <li class="dose child"><strong>For children 6 months&#8211;1 year</strong><br/>
                Initially 100&#8211;200 micrograms/kg every 4 hours, adjusted according to response.</li>
              <li class="dose child"><strong>For children 2&#8211;11 years</strong><br/>
                Initially 200 micrograms/kg every 4 hours, adjusted according to response.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 2.5&#8211;10 mg every 4 hours, adjusted according to response.</li>
              <li class="dose child"><strong>For children 1&#8211;5 months</strong><br/>
                100 micrograms/kg every 6 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 100 micrograms/kg, dose to be administered over at least 5 minutes, followed by (by continuous intravenous infusion) 10&#8211;30 micrograms/kg/hour, adjusted according to response.</li>
              <li class="dose child"><strong>For children 6 months&#8211;11 years</strong><br/>
                100 micrograms/kg every 4 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 100 micrograms/kg, dose to be administered over at least 5 minutes, followed by (by continuous intravenous infusion) 20&#8211;30 micrograms/kg/hour, adjusted according to response.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                5 mg every 4 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 5 mg, dose to be administered over at least 5 minutes, followed by (by continuous intravenous infusion) 20&#8211;30 micrograms/kg/hour, adjusted according to response.</li>
              <li class="dose child"><strong>For children 1&#8211;2 months</strong><br/>
                Initially 50&#8211;100 micrograms/kg every 4 hours, adjusted according to response.</li>
              <li class="dose child"><strong>For children 3&#8211;5 months</strong><br/>
                100&#8211;150 micrograms/kg every 4 hours, adjusted according to response.</li>
              <li class="dose child"><strong>For children 6&#8211;11 months</strong><br/>
                200 micrograms/kg every 4 hours, adjusted according to response.</li>
              <li class="dose child"><strong>For children 1 year</strong><br/>
                Initially 200&#8211;300 micrograms/kg every 4 hours, adjusted according to response.</li>
              <li class="dose child"><strong>For children 2&#8211;11 years</strong><br/>
                Initially 200&#8211;300 micrograms/kg every 4 hours (max. per dose 10 mg), adjusted according to response.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 5&#8211;10 mg every 4 hours, adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute pain</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients, dose can be given more frequently during titration, use dose for elderly in frail patients.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 5 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients, dose can be given more frequently during titration.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients, dose can be adjusted more frequently during titration, reduced dose recommended in frail and elderly patients.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Chronic pain</span>,
            </h4>
            <p class="specificity"><span class="route">By rectum</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5&#8211;10 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 15&#8211;30 mg every 4 hours, adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain (with modified-release 12-hourly preparations)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Every 12 hours, dose adjusted according to daily morphine requirements, dosage requirements should be reviewed if the brand is altered.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain (with modified-release 24-hourly preparations)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Every 24 hours, dose adjusted according to daily morphine requirements, dosage requirements should be reviewed if the brand is altered.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Usual dose 30&#8211;200 mg every 4 hours, for management of breakthrough pain and other general advice, see Pain management with opioids under Prescribing in palliative care.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Usual dose 100&#8211;600 mg every 12 hours, for management of breakthrough pain and other general advice, see Pain management with opioids under Prescribing in palliative care.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain management in palliative care (starting dose for opioid-na&#239;ve patients)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20&#8211;30 mg daily in divided doses, dose for either immediate-release or a 12-hourly modified-release preparation, for management of breakthrough pain and other general advice, see Pain management with opioids under Prescribing in palliative care.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain management in palliative care (starting dose for patients being switched from a regular weak opioid)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                40&#8211;60 mg daily in divided doses, for managment of breakthrough pain and other general advice, see Pain management with opioids under Prescribing in palliative care.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cough in terminal disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg every 4 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Premedication</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Up to 10 mg, dose to be administered 60&#8211;90 minutes before operation.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Patient controlled analgesia (PCA)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult local protocol).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Myocardial infarction</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5&#8211;10 mg, followed by 5&#8211;10 mg if required, dose to be administered at a rate of 1&#8211;2 mg/minute, use dose for elderly in frail patients.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                2.5&#8211;5 mg, followed by 2.5&#8211;5 mg if required, dose to be administered at a rate of 1&#8211;2 mg/minute.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute pulmonary oedema</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5&#8211;10 mg, dose to be administered at a rate of 2 mg/minute, use dose for elderly in frail patients.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                2.5&#8211;5 mg, dose to be administered at a rate of 2 mg/minute.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Persistent cyanosis in congenital heart disease when blood glucose less than 3&#8239;mmol/litre (following glucose)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children </strong><br/>
                100 micrograms/kg.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Dyspnoea in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg every 4 hours, to be given in carefully titrated doses.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>The doses stated refer equally to morphine hydrochloride and sulfate.</p>
            </section>
        
        
        
      </section>





      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Acute abdomen</li>
            <li>delayed gastric emptying</li>
            <li>heart failure secondary to chronic lung disease</li>
            <li>phaeochromocytoma</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Abdominal pain, agitation, amenorrhoea, anorexia, asthenia, bronchospasm, delirium, disorientation, dyspepsia, exacerbation of pancreatitis, excitation, hypertension, hypothermia, inhibition of cough reflex, malaise, muscle fasciculation, myoclonus, nystagmus, paraesthesia, paralytic ileus, raised intracranial pressure, restlessness, rhabdomyolysis, seizures, syncope, taste disturbance,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>continuous intravenous infusion</i>, dilute with Glucose 5% or 10% or Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>
            <i>Neonatal intensive care</i>, dilute 2.5&#8239;mg/kg body-weight to a final volume of 50&#8239;mL with infusion fluid; an intravenous infusion rate of 0.1&#8239;mL/hour provides a dose of 5&#8239;micrograms/kg/hour.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>For <i>modified release capsules</i>&#8212;swallow whole or open capsule and sprinkle contents on soft food.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Patients or carers should be given advice on how to administer morphine modified-release capsules.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Morphine for pain</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/morphine-for-pain">www.medicinesforchildren.org.uk/morphine-for-pain</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiac arrhythmias
          </li>
          <li>
            pancreatitis
          </li>
          <li>
            severe cor pulmonale
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>
            <i>Oramorph</i>
            <tm tmtype="reg"/> solution and <i>MXL</i>
            <tm tmtype="reg"/> capsules not licensed for use in children under 1 year.</p><p>
            <i>Sevredol </i>
            <tm tmtype="reg"/> tablets not licensed for use in children under 3 years.</p><p>
            <i>Oramorph</i>
            <tm tmtype="reg"/> unit dose vials and <i>Filnarine</i>
            <tm tmtype="reg"/> SR tablets not licensed for use in children under 6 years.</p><p>
            <i>MST Continus</i>
            <tm tmtype="reg"/> preparations licensed to treat children with cancer pain (age-range not specified by manufacturer).</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">rectal</ph> use in children</h3>
              <p>Suppositories are not licensed for use in children.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Prescriptions must also specify the 'form'.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">rectal</ph> use</h3>
              <p>Both the strength of the suppositories and the morphine salt contained in them must be specified by the prescriber.</p>
            </section>
      </section>







      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
                <h3>Morphine Oral Solutions</h3>
              <p>Prescription-only medicines or schedule 2 controlled drug. The proportion of morphine hydrochloride may be altered when specified by the prescriber; if above 13&#8239;mg per 5&#8239;mL the solution becomes a schedule 2 controlled drug. It is usual to adjust the strength so that the dose volume is 5 or 10&#8239;mL.</p><p>Oral solutions of morphine can be prescribed by writing the formula:</p><p>Morphine hydrochloride 5&#8239;mg</p><p>Chloroform water to 5&#8239;mL</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of MORPHINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            suppository,
            solution for injection,
            solution for infusion,
            oral solution,
            gel,
            capsule,
            nebuliser liquid,
            infusion,

            <div id="PHP76927"><a href="../medicinalForm/PHP76927.html" data-target="#PHP76927" data-action="load">Tablet</a></div>
            <div id="PHP76935"><a href="../medicinalForm/PHP76935.html" data-target="#PHP76935" data-action="load">Modified-release tablet</a></div>
            <div id="PHP76937"><a href="../medicinalForm/PHP76937.html" data-target="#PHP76937" data-action="load">Modified-release capsule</a></div>
            <div id="PHP76943"><a href="../medicinalForm/PHP76943.html" data-target="#PHP76943" data-action="load">Modified-release granules</a></div>
            <div id="PHP76974"><a href="../medicinalForm/PHP76974.html" data-target="#PHP76974" data-action="load">Oral solution</a></div>
            <div id="PHP76993"><a href="../medicinalForm/PHP76993.html" data-target="#PHP76993" data-action="load">Solution for injection</a></div>
            <div id="PHP76987"><a href="../medicinalForm/PHP76987.html" data-target="#PHP76987" data-action="load">Solution for infusion</a></div>
            <div id="PHP76956"><a href="../medicinalForm/PHP76956.html" data-target="#PHP76956" data-action="load">Suppository</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
